technophage.pt | TechnoPhage, SA | From science to innovative

Robots.txt Information

Robot	Path	Permission
GoogleBot	/	✔
BingBot	/	✔
BaiduSpider	/	✔
YandexBot	/	✔
User-agent: * Disallow: /wp-admin/ Allow: /wp-admin/admin-ajax.php Sitemap: http://technophage.pt/wp-sitemap.xml

Meta Tags

Title	TechnoPhage, SA \| From science to innovative
Description	About us The company Our track record Quality Policy Leadership Board of Directors Management Team Scientific and Clinical Advisors R&D Product Pipeline T
Keywords	N/A

Server Information

WebSite	technophage.pt
Host IP	185.32.190.60
Location	Portugal

Explore mais

Site

radioprogresso.com.br

technophage.pt avaliação

US$2,563,483

Última atualização: 2022-06-26 08:39:27

A classificação global da Semrush para technophage.pt é 4,128,877 . technophage.pt tem um valor estimado de US$2,563,483 com base na receita estimada de anúncios. technophage.pt é acessado por aproximadamente 295,787 usuários únicos a cada dia. Seu servidor web está localizado em Portugal e tem um endereço IP de 185.32.190.60. O SiteAdvisor diz que technophage.pt é seguro para acessar.

Tráfego e valor de cotação

preço de venda	US$2,563,483
receita diária de anúncios	US$2,367
receita mensal de anúncios	US$70,989
receita anual de publicidade	US$851,865
Visitante Único Diário	19,720
Observação: todos os valores de tráfego e receita são estimativas.

DNS Records

Host	Type	TTL	Data
technophage.pt.	A	14400	IP: 185.32.190.60
technophage.pt.	NS	86400	NS Record: ns2.uniodns.com.
technophage.pt.	NS	86400	NS Record: ns1.uniodns.com.
technophage.pt.	MX	14400	MX Record: 10 alt3.aspmx.l.google.com.
technophage.pt.	MX	14400	MX Record: 1 aspmx.l.google.com.
technophage.pt.	MX	14400	MX Record: 5 alt2.aspmx.l.google.com.
technophage.pt.	MX	14400	MX Record: 5 alt1.aspmx.l.google.com.
technophage.pt.	MX	14400	MX Record: 10 alt4.aspmx.l.google.com.
technophage.pt.	TXT	14400	TXT Record: v=spf1 +a +mx +ip4:185.32.190.60 +ip4:185.32.188.137 +include:_spf.ptservidor.net ~all

HtmlToTextCheckTime:2022-06-26 08:39:27

About us The company Our track record Quality Policy Leadership Board of Directors Management Team Scientific and Clinical Advisors R&D Product Pipeline Therapeutic areas GMP manufacturing Patients Expanded Access News Room Contacts Select Page About us The company Our track record Quality Policy Leadership Board of Directors Management Team Scientific and Clinical Advisors R&D Product Pipeline Therapeutic areas GMP manufacturing Patients Expanded Access News Room Contacts From Science to Innovative Biopharmaceuticals Infection Neurosciences Ophthalmology # News Room TechnoPhage Announces First Clinical Safety Results with Innovative Biological Product TP-102 4 Nov 2021 TechnoPhage is proud to announce that the first part of the Phase I/IIa Clinical Trial with TP-102 (REVERSE study) has been completed. The study... Technophage Annual Meeting 2021 18 Out 2021 Last week TechnoPhage held its Annual Meeting where the CEO, Miguel Garcia, took the opportunity to speak to the collaborators

HTTP Headers

HTTP/1.1 200 OK
Date: Mon, 25 Oct 2021 11:38:57 GMT
Server: Apache
X-Powered-By: PHP/7.3.31
Link: ; rel="https://api.w.org/", ; rel="alternate"; type="application/json", ; rel=shortlink
Upgrade: h2,h2c
Connection: Upgrade
Content-Type: text/html; charset=UTF-8

technophage.pt Avaliação e análise